

## ASX Listing Rules

### Chapter 4 (Appendix 4C) - Quarterly report for entities admitted - Quarterly report for entities admitted on the basis of commitments

#### Rule 4.7B

Introduced 31/3/2000. Amended 30/9/2001

Name of entity
SCIGEN LTD

ABN	Quarter ended ("current quarter")
101 318 852	31 MARCH 2012

#### Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter US\$'000	Year to date (3 months) US\$'000
1.1	Receipts from customers	4,745	4,745
1.2	Payments for		
	(a) staff costs	(1,152)	(1,152)
	(b) advertising and marketing	(254)	(254)
	(c) research and development	(29)	(29)
	(d) leased assets	-	-
	(e) other working capital	(3,778)	(3,778)
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature received	9	9
1.5	Interest and other costs of finance paid	(60)	(60)
1.6	Income taxes paid	-	-
1.7	Other (provide details if material)	8	8
	<b>Net operating cash flows</b>	<b>(511)</b>	<b>(511)</b>

1.8	Net operating cash flows (carried forward)	(511)	(511)
	<b>Cash flows related to investing activities</b>		
1.9	Payment for acquisition of:		
	(a) businesses (item 5)*	-	-
	(b) equity investments*	-	-
	(c) intangible assets	(8)	(8)
	(d) physical non-current assets	(18)	(18)
	(e) other non-current assets - reclassified from "other working capital"	-	-
1.10	Proceeds from disposal of:		
	(a) businesses – partial proceeds for disposal of subsidiary in Israel, SciGen (I.L.) Ltd	150	150
	(b) equity investments	-	-
	(c) intangible assets	-	-
	(d) physical non-current assets	7	7
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
	<b>Net investing cash flows</b>	131	131
1.14	<b>Total operating and investing cash flows</b>	(380)	(380)
	<b>Cash flows related to financing activities</b>		
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Others :		
	(i) Loans from holding company (repayable in Dec 2015)	-	-
	(ii) Loan from third-party entity (convertible to shares of a subsidiary in India)	1,950	1,950
	<b>Net financing cash flows</b>	1,950	1,950
	<b>Net increase/(decrease) in cash held</b>	1,570	1,570
1.21	Cash at beginning of quarter/year to date	1,997	1,997
1.22	Exchange rate adjustments to item 1.20	(12)	(12)
1.23	<b>Cash at end of quarter</b>	3,555	3,555

**Payments to directors of the entity and associates of the directors**  
**Payments to related entities of the entity and associates of the related entities**

		Current quarter US\$'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(104)
1.25	Aggregate amount of loans to the parties included in item 1.11	-
1.26	Explanation necessary for an understanding of the transactions  1.24 Consists of director's remuneration and benefits.	

**Non-cash financing and investing activities**

2.1	Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows  N/A
2.2	Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest  N/A

**Financing facilities available**

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available US\$'000	Amount used US\$'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter US\$'000	Previous quarter US\$'000
4.1	Cash on hand and at bank	3,404	1,851
4.2	Deposits at call	151	146
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
	<b>Total: cash at end of quarter (item 1.22)</b>	<b>3,555</b>	<b>1,997</b>

## Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	-	Hefei-SciGen-Bioton Biopharmaceutical Company Ltd
5.2	Place of incorporation or registration	-	People's Republic of China
5.3	Consideration for acquisition or disposal	-	US\$3.46 million
5.4	Total net assets (Company's share at 51%)	-	US\$3.46 million
5.5	Nature of business	-	Manufacturing, sales and marketing of biopharmaceutical products

## Compliance statement

1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2 This statement does ~~does not~~\* (*delete one*) give a true and fair view of the matters disclosed.



26 April 2012

Sign here: ..... Date: .....  
(Director / Company secretary)

Jenny Low

Print name: .....

## Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2. The definitions in, and provisions of, *AASB 1026: Statement of Cash Flows* apply to this report except for the paragraphs of the Standard set out below.

- 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
- 9.2 - itemised disclosure relating to acquisitions
- 9.4 - itemised disclosure relating to disposals
- 12.1(a) - policy for classification of cash items
- 12.3 - disclosure of restrictions on use of cash
- 13.1 - comparative information

- **3. Accounting Standards.** ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

Copyright by the Australian Stock Exchange Limited. All rights reserved.